{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T21:02:33Z","timestamp":1775595753535,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40256-024-00649-1","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T11:02:18Z","timestamp":1715079738000},"page":"523-535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating the Effectiveness and Safety of Evinacumab in Treating Hypercholesterolemia and Hypertriglyceridemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2167-3481","authenticated-orcid":false,"given":"Hussain Sohail","family":"Rangwala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hareer","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirha","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ashir","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burhanuddin Sohail","family":"Rangwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikash","family":"Virwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Ali","family":"Arsal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adarsh","family":"Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandesh","family":"Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Saqlain","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"649_CR1","doi-asserted-by":"publisher","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update From the GBD 2019 Study [published correction appears in J Am Coll Cardiol. 2021;77(15):1958\u20131959]. J Am Coll Cardiol. 2020;76(25):2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010.","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"649_CR2","doi-asserted-by":"crossref","unstructured":"Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, et al. Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia. JAMA Cardiol [Internet]. 2023 Nov 1 [cited 2023 Nov 24];8(11). https:\/\/pubmed.ncbi.nlm.nih.gov\/37703006\/.","DOI":"10.1001\/jamacardio.2023.2921"},{"key":"649_CR3","doi-asserted-by":"crossref","unstructured":"Bor\u00e9n J, John Chapman M, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J [Internet]. 2020 Jun 21 [cited 2023 Nov 24];41(24):2313\u201330. https:\/\/pubmed.ncbi.nlm.nih.gov\/32052833\/.","DOI":"10.1093\/eurheartj\/ehz962"},{"key":"649_CR4","doi-asserted-by":"crossref","unstructured":"Paththinige CS, Sirisena ND, Dissanayake VHW. Genetic determinants of inherited susceptibility to hypercholesterolemia - a comprehensive literature review. Lipids Health Dis [Internet]. 2017 Jun 2 [cited 2023 Nov 24];16(1). https:\/\/pubmed.ncbi.nlm.nih.gov\/28577571\/.","DOI":"10.1186\/s12944-017-0488-4"},{"issue":"25","key":"649_CR5","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","volume":"44","author":"M Cuchel","year":"2023","unstructured":"Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277\u201391. https:\/\/doi.org\/10.1093\/eurheartj\/ehad197.","journal-title":"Eur Heart J"},{"key":"649_CR6","doi-asserted-by":"crossref","unstructured":"Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers [Internet]. 2017 [cited 2023 Nov 24];3(1). https:\/\/pubmed.ncbi.nlm.nih.gov\/29219151\/.","DOI":"10.1038\/nrdp.2017.93"},{"key":"649_CR7","doi-asserted-by":"crossref","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet [Internet]. 2010 Nov 13 [cited 2023 Nov 24];376(9753):1670\u201381. https:\/\/pubmed.ncbi.nlm.nih.gov\/21067804\/.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"649_CR8","doi-asserted-by":"crossref","unstructured":"Waters DD, Brotons C, Chiang CW, Ferri\u00e8res J, Foody J, Jukema JW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation [Internet]. 2009 Jul 7 [cited 2023 Nov 24];120(1):28\u201334. https:\/\/pubmed.ncbi.nlm.nih.gov\/19546386\/.","DOI":"10.1161\/CIRCULATIONAHA.108.838466"},{"key":"649_CR9","doi-asserted-by":"crossref","unstructured":"Wang X, Musunuru K. Angiopoietin-like 3: from discovery to therapeutic gene editing. JACC Basic Transl Sci [Internet]. 2019 Oct 1 [cited 2023 Nov 24];4(6):755\u201362. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31709322\/.","DOI":"10.1016\/j.jacbts.2019.05.008"},{"key":"649_CR10","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med [Internet]. 2017 May 4 [cited 2023 Nov 24];376(18):1713\u201322. https:\/\/pubmed.ncbi.nlm.nih.gov\/28304224\/.","DOI":"10.1056\/NEJMoa1615664"},{"key":"649_CR11","doi-asserted-by":"crossref","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med [Internet]. 2018 Nov 29 [cited 2023 Nov 24];379(22):2097\u2013107. https:\/\/pubmed.ncbi.nlm.nih.gov\/30403574\/.","DOI":"10.1056\/NEJMoa1801174"},{"key":"649_CR12","doi-asserted-by":"crossref","unstructured":"Rosenson RS. Existing and emerging therapies for the treatment of familial hypercholesterolemia. J Lipid Res [Internet]. 2021 Apr 1 [cited 2023 Nov 24];62. https:\/\/pubmed.ncbi.nlm.nih.gov\/33716107\/.","DOI":"10.1016\/j.jlr.2021.100060"},{"key":"649_CR13","doi-asserted-by":"crossref","unstructured":"Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med [Internet]. 2017 Jul 20 [cited 2023 Nov 24];377(3):211\u201321. https:\/\/pubmed.ncbi.nlm.nih.gov\/28538136\/.","DOI":"10.1056\/NEJMoa1612790"},{"key":"649_CR14","doi-asserted-by":"crossref","unstructured":"Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med [Internet]. 2020 Dec 10 [cited 2023 Nov 24];383(24):2307\u201319. https:\/\/pubmed.ncbi.nlm.nih.gov\/33196153\/.","DOI":"10.1056\/NEJMoa2031049"},{"key":"649_CR15","doi-asserted-by":"crossref","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med [Internet]. 2020 Aug 20 [cited 2023 Nov 24];383(8):711\u201320. https:\/\/pubmed.ncbi.nlm.nih.gov\/32813947\/.","DOI":"10.1056\/NEJMoa2004215"},{"key":"649_CR16","doi-asserted-by":"crossref","unstructured":"Banerjee P, Chan KC, Tarabocchia M, Benito-Vicente A, Alves AC, Uribe KB, et al. Functional analysis of LDLR (Low-Density Lipoprotein Receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity. Arterioscler Thromb Vasc Biol [Internet]. 2019 [cited 2023 Nov 24];39(11):2248\u201360. https:\/\/pubmed.ncbi.nlm.nih.gov\/31578082\/.","DOI":"10.1161\/ATVBAHA.119.313051"},{"key":"649_CR17","doi-asserted-by":"crossref","unstructured":"Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, Sasiela WJ, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation [Internet]. 2019 Aug 6 [cited 2023 Nov 24];140(6):470\u201386. https:\/\/pubmed.ncbi.nlm.nih.gov\/31242752\/.","DOI":"10.1161\/CIRCULATIONAHA.118.039107"},{"key":"649_CR18","doi-asserted-by":"crossref","unstructured":"Harada-Shiba M, Ali S, Gipe DA, Gasparino E, Son V, Zhang Y, et al. A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. Atherosclerosis [Internet]. 2020 Dec 1 [cited 2023 Nov 24];314:33\u201340. https:\/\/pubmed.ncbi.nlm.nih.gov\/33130482\/.","DOI":"10.1016\/j.atherosclerosis.2020.10.013"},{"key":"649_CR19","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 Mar 29 [cited 2023 Aug 26];372. https:\/\/pubmed.ncbi.nlm.nih.gov\/33782057\/."},{"key":"649_CR20","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 [cited 2023 Aug 26];366. https:\/\/pubmed.ncbi.nlm.nih.gov\/31462531\/.","DOI":"10.1136\/bmj.l4898"},{"key":"649_CR21","doi-asserted-by":"crossref","unstructured":"Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med [Internet]. 2023 [cited 2024 Feb 6];29(3). https:\/\/pubmed.ncbi.nlm.nih.gov\/36879129\/.","DOI":"10.1038\/s41591-023-02222-w"},{"key":"649_CR22","first-page":"253","volume":"1","author":"GF Watts","year":"2023","unstructured":"Watts GF, Chan DC, Raal FJ. Inhibition of ANGPTL3 as a target for treating dyslipidemias. Clin Lipidol Companion Braunwald\u2019s Heart Dis. 2023;1:253-267.e1.","journal-title":"Clin Lipidol Companion Braunwald\u2019s Heart Dis"},{"key":"649_CR23","doi-asserted-by":"crossref","unstructured":"Pirillo A, Catapano AL. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia. Expert Opin Biol Ther [Internet]. 2022 [cited 2024 Feb 6];22(7):813\u201320. https:\/\/pubmed.ncbi.nlm.nih.gov\/35698895\/.","DOI":"10.1080\/14712598.2022.2090242"},{"key":"649_CR24","unstructured":"Patel N, Parmar M, Patel P. Evinacumab. StatPearls [Internet]. 2023 Oct 28 [cited 2024 Feb 6]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK597342\/."},{"issue":"7","key":"649_CR25","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1194\/jlr.M054890","volume":"56","author":"V Gusarova","year":"2015","unstructured":"Gusarova V, Alexa CA, Wang Y, Rafique A, Kim JH, Buckler D, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res [Internet]. 2015;56(7):1308 (pmc\/articles\/PMC4479335).","journal-title":"J Lipid Res [Internet]"},{"key":"649_CR26","doi-asserted-by":"crossref","unstructured":"Jin M, Meng F, Yang W, Liang L, Wang H, Fu Z. Efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis. J Cardiovasc Pharmacol [Internet]. 2021 Sep 11 [cited 2024 Feb 6];78(3):394\u2013402. https:\/\/pubmed.ncbi.nlm.nih.gov\/34117182\/.","DOI":"10.1097\/FJC.0000000000001073"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00649-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00649-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00649-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T03:23:10Z","timestamp":1767496990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00649-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["649"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00649-1","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"22 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hussain Sohail Rangwala, Hareer Fatima, Mirha Ali, Muhammad Ashir Shafique, Burhanuddin Sohail Rangwala, Vikash Virwani, Aashish Kumar, Syed Ali Arsal, Adarsh Raja, Sandesh Raja, and Muhammad Saqlain Mustafa declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The conceptualization was done by HSR and MSM. The literature and drafting of the manuscript were conducted by HF, HSR, MA, MAS, VV, AK, BSR, AR, SR, and SAA. The editing and supervision were performed by HSR. All authors have read and agreed to the final version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}